patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_706274 | REC_0006201 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 32 | 8.5 | 63 | female | 1 | 20 | 5.5 | 1 | pembrolizumab 200 mg q3w | 13.8 | false | MSS | 2026-03-15T05:35:58.377550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_898810 | REC_0006202 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 14 | 68 | female | 0 | 20 | 3.6 | 1 | osimertinib 80 mg daily | 24.7 | false | MSS | 2026-03-15T05:35:58.377834+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_966347 | REC_0006203 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.5 | 53 | female | 0 | 73 | 4.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.1 | false | MSS | 2026-03-15T05:35:58.378070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_145453 | REC_0006204 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 6.3 | 65 | male | 0 | 3 | 5.3 | 2 | alectinib 600 mg BID | 12.6 | true | MSS | 2026-03-15T05:35:58.378305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280944 | REC_0006205 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 15.7 | 73 | female | 2 | 4 | 6.5 | 8 | osimertinib 80 mg daily | 12.1 | true | MSI-H | 2026-03-15T05:35:58.378537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371240 | REC_0006206 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 34 | 1.5 | 50 | female | 0 | 37 | 6.4 | 2 | pembrolizumab 200 mg q3w | 17.6 | true | MSS | 2026-03-15T05:35:58.378771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_431582 | REC_0006207 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 15.8 | 76 | female | 2 | 12 | 3.8 | 5 | osimertinib 80 mg daily | 10.9 | true | MSS | 2026-03-15T05:35:58.379004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_913684 | REC_0006208 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.7 | 73 | female | 2 | 40 | 5.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 11 | true | MSS | 2026-03-15T05:35:58.379233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747682 | REC_0006209 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 6.9 | 75 | female | 2 | 44 | 5.3 | 8 | pembrolizumab 200 mg q3w | 14.1 | false | MSS | 2026-03-15T05:35:58.379460+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_348874 | REC_0006210 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 10.1 | 71 | female | 2 | 16 | 6.2 | 8 | osimertinib 80 mg daily | 17.4 | true | MSS | 2026-03-15T05:35:58.379690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429524 | REC_0006211 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 15.6 | 50 | male | 0 | 16 | 4.5 | 8 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.379925+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896195 | REC_0006212 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 7.8 | 71 | male | 1 | 6 | 4.1 | 3 | carboplatin + paclitaxel + pembrolizumab | 18.4 | false | MSS | 2026-03-15T05:35:58.380183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780430 | REC_0006213 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 35 | 5.6 | 66 | female | 0 | 13 | 4.2 | 5 | sotorasib 960 mg daily | 15.6 | false | MSS | 2026-03-15T05:35:58.380416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340070 | REC_0006214 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 18.3 | 67 | male | 1 | 14 | 5.5 | 1 | osimertinib 80 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:58.380656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558015 | REC_0006215 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 5.5 | 65 | female | 0 | 9 | 3.9 | 1 | pembrolizumab 200 mg q3w | 15.4 | true | MSS | 2026-03-15T05:35:58.380933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_627147 | REC_0006216 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 7.9 | 67 | female | 0 | 16 | 5.2 | 6 | pembrolizumab 200 mg q3w | 12.8 | false | MSS | 2026-03-15T05:35:58.381164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_156386 | REC_0006217 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 10.9 | 74 | female | 3 | 22 | 4.8 | 5 | osimertinib 80 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:58.381399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742166 | REC_0006218 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 10.4 | 67 | female | 0 | 30 | 6.9 | 6 | osimertinib 80 mg daily | 12.1 | true | MSS | 2026-03-15T05:35:58.381631+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895727 | REC_0006219 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 15.5 | 58 | female | 1 | 11 | 6.1 | 5 | alectinib 600 mg BID | 4.5 | true | MSI-H | 2026-03-15T05:35:58.381866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872294 | REC_0006220 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 3.8 | 75 | female | 2 | 68 | 4.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.9 | false | MSS | 2026-03-15T05:35:58.382094+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538739 | REC_0006221 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 16.1 | 54 | male | 0 | 17 | 5.4 | 3 | entrectinib 600 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:58.382328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835469 | REC_0006222 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 7.3 | 65 | male | 0 | 18 | 4.7 | 5 | osimertinib 80 mg daily | 14.5 | true | MSS | 2026-03-15T05:35:58.382558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573836 | REC_0006223 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 10.2 | 76 | female | 1 | 15 | 4.2 | 2 | sotorasib 960 mg daily | 27.7 | false | MSI-H | 2026-03-15T05:35:58.382792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_209930 | REC_0006224 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 7.9 | 74 | female | 1 | 54 | 5.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.2 | true | MSS | 2026-03-15T05:35:58.383019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_125309 | REC_0006225 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 5 | 90 | female | 1 | 74 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.5 | false | MSS | 2026-03-15T05:35:58.383247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183308 | REC_0006226 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 17.2 | 62 | female | 0 | 9 | 4.8 | 1 | sotorasib 960 mg daily | 17.1 | true | MSI-H | 2026-03-15T05:35:58.383482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997088 | REC_0006227 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 12.3 | 81 | female | 3 | 17 | 4.6 | 6 | sotorasib 960 mg daily | 7.5 | false | MSS | 2026-03-15T05:35:58.383713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560683 | REC_0006228 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 15 | 80 | female | 2 | 14 | 4.4 | 9 | entrectinib 600 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:58.383994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224220 | REC_0006229 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 10.6 | 63 | female | 0 | 17 | 7.6 | 1 | osimertinib 80 mg daily | 19.9 | true | MSI-H | 2026-03-15T05:35:58.384262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537326 | REC_0006230 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 21 | 13.8 | 61 | male | 1 | 12 | 5.2 | 0 | sotorasib 960 mg daily | 44.6 | false | MSS | 2026-03-15T05:35:58.384503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271244 | REC_0006231 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 8.1 | 73 | female | 1 | 2 | 6.8 | 4 | entrectinib 600 mg daily | 7.9 | false | MSS | 2026-03-15T05:35:58.384738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_718774 | REC_0006232 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 36 | 15.3 | 72 | female | 2 | 20 | 7.4 | 5 | osimertinib 80 mg daily | 8.6 | true | MSI-H | 2026-03-15T05:35:58.384968+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655541 | REC_0006233 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 15.2 | 72 | female | 2 | 15 | 5.1 | 6 | entrectinib 600 mg daily | 13.7 | false | MSI-H | 2026-03-15T05:35:58.385200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406230 | REC_0006234 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 12.8 | 87 | male | 1 | 15 | 4 | 1 | osimertinib 80 mg daily | 9.9 | false | MSS | 2026-03-15T05:35:58.385435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_471517 | REC_0006235 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 13.8 | 60 | female | 1 | 13 | 5.2 | 7 | pembrolizumab 200 mg q3w | 18.2 | true | MSS | 2026-03-15T05:35:58.385669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_666949 | REC_0006236 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 15 | 13.7 | 61 | female | 0 | 9 | 6.7 | 2 | pembrolizumab 200 mg q3w | 5.8 | true | MSI-H | 2026-03-15T05:35:58.385903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_972282 | REC_0006237 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11.6 | 75 | male | 1 | 19 | 6.3 | 5 | entrectinib 600 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:58.386139+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159141 | REC_0006238 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 10.3 | 60 | female | 0 | 1 | 4.5 | 8 | entrectinib 600 mg daily | 7.8 | true | MSS | 2026-03-15T05:35:58.386370+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_821740 | REC_0006239 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 15.3 | 66 | female | 1 | 14 | 4.3 | 6 | entrectinib 600 mg daily | 15.5 | false | MSS | 2026-03-15T05:35:58.386605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777620 | REC_0006240 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 18 | 69 | female | 1 | 18 | 5.7 | 5 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:58.386837+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_491551 | REC_0006241 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 32 | 6.8 | 62 | female | 1 | 10 | 5.5 | 6 | pembrolizumab 200 mg q3w | 7.8 | false | MSS | 2026-03-15T05:35:58.387111+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_605983 | REC_0006242 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 4.9 | 74 | female | 2 | 27 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 25.8 | true | MSS | 2026-03-15T05:35:58.387343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709163 | REC_0006243 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 7.1 | 68 | female | 1 | 20 | 7.8 | 6 | pembrolizumab 200 mg q3w | 9.8 | true | MSS | 2026-03-15T05:35:58.387573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169691 | REC_0006244 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 8.5 | 72 | male | 2 | 15 | 3.9 | 5 | sotorasib 960 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:58.387806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307442 | REC_0006245 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 16 | 8.9 | 69 | female | 1 | 15 | 6.6 | 2 | pembrolizumab 200 mg q3w | 13.3 | false | MSS | 2026-03-15T05:35:58.388034+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705640 | REC_0006246 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.5 | 54 | female | 0 | 19 | 6.8 | 5 | alectinib 600 mg BID | 6.4 | false | MSS | 2026-03-15T05:35:58.388317+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_710225 | REC_0006247 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 14 | 53 | female | 0 | 20 | 3.9 | 0 | sotorasib 960 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:58.388557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387520 | REC_0006248 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 5.4 | 75 | male | 1 | 41 | 4.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 7 | false | MSS | 2026-03-15T05:35:58.388803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_870413 | REC_0006249 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 4.8 | 68 | female | 1 | 13 | 5.7 | 1 | osimertinib 80 mg daily | 26.4 | false | MSS | 2026-03-15T05:35:58.389032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405644 | REC_0006250 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 14.5 | 68 | female | 1 | 11 | 6 | 5 | osimertinib 80 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:58.389266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832100 | REC_0006251 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 12.3 | 64 | female | 1 | 22 | 6.2 | 7 | sotorasib 960 mg daily | 12 | false | MSI-H | 2026-03-15T05:35:58.389500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289474 | REC_0006252 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 9.8 | 72 | female | 1 | 15 | 5 | 8 | entrectinib 600 mg daily | 10.4 | false | MSS | 2026-03-15T05:35:58.389727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812155 | REC_0006253 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 12.1 | 77 | female | 2 | 21 | 6.9 | 8 | entrectinib 600 mg daily | 11.2 | true | MSI-H | 2026-03-15T05:35:58.389962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499569 | REC_0006254 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 15.8 | 62 | female | 1 | 15 | 5.1 | 7 | sotorasib 960 mg daily | 9.7 | true | MSS | 2026-03-15T05:35:58.390245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885156 | REC_0006255 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 21 | 7 | 65 | male | 0 | 53 | 6.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 31 | false | MSS | 2026-03-15T05:35:58.390482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616201 | REC_0006256 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 20 | 4.8 | 63 | female | 1 | 13 | 6 | 0 | entrectinib 600 mg daily | 21.2 | false | MSS | 2026-03-15T05:35:58.390713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691454 | REC_0006257 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 7.4 | 61 | male | 1 | 14 | 6.6 | 4 | pembrolizumab 200 mg q3w | 5.4 | false | MSS | 2026-03-15T05:35:58.390946+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245079 | REC_0006258 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 22 | 2.3 | 58 | female | 0 | 41 | 6.1 | 0 | carboplatin + paclitaxel + pembrolizumab | 37.8 | true | MSS | 2026-03-15T05:35:58.391175+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598988 | REC_0006259 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 13 | 8.8 | 58 | male | 0 | 25 | 4.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.2 | false | MSS | 2026-03-15T05:35:58.391409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269787 | REC_0006260 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 11.4 | 70 | female | 2 | 5 | 3.9 | 6 | alectinib 600 mg BID | 8.7 | false | MSI-H | 2026-03-15T05:35:58.391643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_631700 | REC_0006261 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 8.5 | 60 | male | 1 | 6 | 6.2 | 5 | entrectinib 600 mg daily | 13.9 | false | MSS | 2026-03-15T05:35:58.391876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871804 | REC_0006262 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 4.5 | 54 | female | 0 | 65 | 6.1 | 2 | pembrolizumab 200 mg q3w | 23 | false | MSS | 2026-03-15T05:35:58.392209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868440 | REC_0006263 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 10.6 | 66 | female | 0 | 6 | 6 | 8 | osimertinib 80 mg daily | 13.3 | true | MSS | 2026-03-15T05:35:58.392455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_193809 | REC_0006264 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 21 | 4.6 | 73 | female | 2 | 15 | 5.7 | 0 | osimertinib 80 mg daily | 43.6 | true | MSS | 2026-03-15T05:35:58.392683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226259 | REC_0006265 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 38 | 10.5 | 69 | female | 0 | 3 | 5.6 | 1 | osimertinib 80 mg daily | 19.8 | false | MSI-H | 2026-03-15T05:35:58.392916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572444 | REC_0006266 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 13.6 | 73 | female | 2 | 18 | 6.2 | 4 | pembrolizumab 200 mg q3w | 12.6 | true | MSI-H | 2026-03-15T05:35:58.393147+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362395 | REC_0006267 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 8 | 64 | female | 1 | 19 | 5.8 | 4 | alectinib 600 mg BID | 14.2 | true | MSS | 2026-03-15T05:35:58.393424+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212679 | REC_0006268 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 11.9 | 73 | female | 1 | 14 | 5.9 | 6 | alectinib 600 mg BID | 16.4 | false | MSI-H | 2026-03-15T05:35:58.393657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997360 | REC_0006269 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 12.9 | 51 | male | 0 | 9 | 5.8 | 8 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:35:58.393892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235590 | REC_0006270 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 29 | 15.6 | 69 | female | 1 | 19 | 4.5 | 0 | osimertinib 80 mg daily | 36 | false | MSS | 2026-03-15T05:35:58.394123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975666 | REC_0006271 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 13.9 | 79 | female | 2 | 17 | 6.2 | 4 | osimertinib 80 mg daily | 12.6 | false | MSI-H | 2026-03-15T05:35:58.394355+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712178 | REC_0006272 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 17 | 4.6 | 52 | female | 0 | 56 | 5.2 | 6 | pembrolizumab 200 mg q3w | 13.9 | true | MSS | 2026-03-15T05:35:58.394585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617015 | REC_0006273 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 23 | 10.4 | 60 | male | 1 | 16 | 7.9 | 0 | osimertinib 80 mg daily | 29.9 | true | MSS | 2026-03-15T05:35:58.394821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250364 | REC_0006274 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 16 | 14 | 67 | male | 1 | 19 | 5.4 | 2 | entrectinib 600 mg daily | 15 | false | MSS | 2026-03-15T05:35:58.395059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148877 | REC_0006275 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 18 | 80 | female | 2 | 6 | 4.8 | 9 | alectinib 600 mg BID | 6.3 | false | MSI-H | 2026-03-15T05:35:58.395287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969478 | REC_0006276 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 5.2 | 78 | female | 3 | 37 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.4 | true | MSS | 2026-03-15T05:35:58.395515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573932 | REC_0006277 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.3 | 64 | male | 0 | 15 | 7.4 | 7 | alectinib 600 mg BID | 15.4 | true | MSS | 2026-03-15T05:35:58.395747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364910 | REC_0006278 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 5.7 | 73 | male | 1 | 41 | 5.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.2 | false | MSS | 2026-03-15T05:35:58.395981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300310 | REC_0006279 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.3 | 65 | male | 1 | 35 | 5.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.5 | false | MSS | 2026-03-15T05:35:58.396301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_266825 | REC_0006280 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 9.5 | 74 | female | 3 | 18 | 5.7 | 5 | osimertinib 80 mg daily | 10.3 | false | MSS | 2026-03-15T05:35:58.396581+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175475 | REC_0006281 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 29 | 14.3 | 62 | male | 0 | 10 | 6.1 | 0 | osimertinib 80 mg daily | 43.3 | true | MSS | 2026-03-15T05:35:58.396821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247903 | REC_0006282 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 10 | 71 | female | 1 | 14 | 4.9 | 8 | alectinib 600 mg BID | 4.4 | false | MSI-H | 2026-03-15T05:35:58.397052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928049 | REC_0006283 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 12.5 | 72 | male | 1 | 11 | 3.5 | 4 | alectinib 600 mg BID | 11 | true | MSI-H | 2026-03-15T05:35:58.397287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997201 | REC_0006284 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.8 | 70 | female | 1 | 52 | 4.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 4.8 | false | MSS | 2026-03-15T05:35:58.397515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910191 | REC_0006285 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 13.8 | 77 | female | 2 | 17 | 4.1 | 1 | alectinib 600 mg BID | 14.1 | false | MSI-H | 2026-03-15T05:35:58.397747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958238 | REC_0006286 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 12 | 11.8 | 70 | male | 1 | 23 | 4.8 | 2 | osimertinib 80 mg daily | 23.6 | true | MSI-H | 2026-03-15T05:35:58.397982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207731 | REC_0006287 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 14.3 | 71 | female | 1 | 31 | 5.6 | 5 | entrectinib 600 mg daily | 9.9 | true | MSI-H | 2026-03-15T05:35:58.398214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184561 | REC_0006288 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 10 | 2.6 | 62 | female | 0 | 7 | 5.8 | 8 | carboplatin + paclitaxel + pembrolizumab | 11.3 | true | MSS | 2026-03-15T05:35:58.398445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961246 | REC_0006289 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 10 | 77 | female | 3 | 10 | 5.6 | 0 | osimertinib 80 mg daily | 33.4 | true | MSI-H | 2026-03-15T05:35:58.398678+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939127 | REC_0006290 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 30 | 8.1 | 63 | male | 1 | 18 | 5.8 | 0 | osimertinib 80 mg daily | 36.4 | true | MSS | 2026-03-15T05:35:58.398909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760538 | REC_0006291 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 10.2 | 55 | male | 1 | 25 | 8.7 | 1 | osimertinib 80 mg daily | 15.1 | true | MSI-H | 2026-03-15T05:35:58.399143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777139 | REC_0006292 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 8.9 | 74 | female | 2 | 21 | 4.5 | 1 | pembrolizumab 200 mg q3w | 17.6 | true | MSS | 2026-03-15T05:35:58.399371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707659 | REC_0006293 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 7.9 | 72 | female | 1 | 23 | 6.3 | 4 | osimertinib 80 mg daily | 16.4 | false | MSS | 2026-03-15T05:35:58.399643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_424900 | REC_0006294 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 14 | 67 | female | 0 | 17 | 4.2 | 1 | entrectinib 600 mg daily | 18.1 | false | MSI-H | 2026-03-15T05:35:58.399880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189675 | REC_0006295 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 7.2 | 77 | male | 2 | 62 | 5.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.4 | false | MSS | 2026-03-15T05:35:58.400173+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191554 | REC_0006296 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 6.4 | 65 | female | 0 | 79 | 7.8 | 4 | pembrolizumab 200 mg q3w | 7.7 | false | MSS | 2026-03-15T05:35:58.400413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540539 | REC_0006297 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 18.3 | 66 | female | 1 | 6 | 7.4 | 1 | osimertinib 80 mg daily | 9.3 | false | MSI-H | 2026-03-15T05:35:58.400660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393281 | REC_0006298 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 16.6 | 82 | female | 2 | 14 | 6.5 | 2 | alectinib 600 mg BID | 16.1 | true | MSI-H | 2026-03-15T05:35:58.400894+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900030 | REC_0006299 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 10.8 | 58 | male | 0 | 12 | 4.2 | 5 | osimertinib 80 mg daily | 14.7 | true | MSI-H | 2026-03-15T05:35:58.401129+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331142 | REC_0006300 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 13.3 | 70 | female | 1 | 12 | 5 | 1 | osimertinib 80 mg daily | 19 | true | MSS | 2026-03-15T05:35:58.401361+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.